Search Results

You are looking at 11 - 20 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu and Peter Fasching

cohort studies and recent clinical trials in the literature. Methods: English publications reporting association between pCR and survival outcomes among TNBC patients receiving neoadjuvant chemotherapy were searched in MEDLINE, EMBASE, Cochrane CENTRAL

Full access

Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma and Hai-Qiang Mai

, concurrent chemoradiotherapy; EBV, Epstein-Barr virus; NACT, neoadjuvant chemotherapy; NPC, nasopharyngeal carcinoma. Pretreatment Evaluation All patients underwent a complete physical examination, fiberoptic nasopharyngoscopy, electrocardiography, MRI of the

Full access

Shannon Ugarte, Annie Tang, Zhonet Harper, Rohan E. John, Kala Mehta, Amal Khoury and Kevin Knopf

To review racial differences in a safety net hospital in pathologic complete response (pCR) rate and outcome of neoadjuvant chemotherapy (NACT) for invasive breast cancer at a safety-net hospital. This is a retrospective cohort study of women

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar and Leonard B. Saltz

statistically significant rate of increased pathCR, or improvement in rates of failure-free or overall survivals, when comparing neoadjuvant chemotherapy followed by chemoradiotherapy and then surgery and adjuvant chemotherapy versus chemoradiotherapy followed

Full access

Sumanta K. Pal, Matthew I. Milowsky and Elizabeth R. Plimack

systemic treatments for bladder cancer. 7 Because of the already broad scope of this review, combined modality treatment (ie, chemoradiation) is not discussed. Neoadjuvant Chemotherapy For nonmetastatic, muscle-invasive bladder cancer (MIBC) staged

Full access

Colby J. Hyland, Flora Varghese, Christina Yau, Heather Beckwith, Katia Khoury, William Varnado, Gillian L. Hirst, Robert R. Flavell, A. Jo Chien, Douglas Yee, Claudine J. Isaacs, Andres Forero-Torres, Laura J. Esserman and Michelle E. Melisko

nodules, and enlarged and/or hypermetabolic lymph nodes (not including the axilla or internal mammary chains). Time to initiation of neoadjuvant chemotherapy was the number of days between the date of core biopsy–proved cancer diagnosis and the date that

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger and Stacy M. Fischer

assessment of a patient's functional age and longevity can help direct more appropriate treatment on an individual basis. Figure 1. Algorithm for treatment of muscle-invasive bladder cancer in elderly patients. Abbreviations: NAC, neoadjuvant chemotherapy; RT

Full access

Christopher M. Booth, Sulaiman Nanji, Xuejiao Wei, Yingwei Peng, James J. Biagi, Timothy P. Hanna, Monika K. Krzyzanowska and William J. Mackillop

Identification of study population. Abbreviation: NACT, neoadjuvant chemotherapy. did not differ substantially from those of the 18,094 unselected cases ( see supplemental eTable 1 and eFigure 1, available with this article at JNCCN.org ). Among the 7

Full access

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman and Hanneke W.M. van Laarhoven

curative cohorts. Another limitation is that information about treatment intent is not included in the NCR because it includes only the treatments patients actually received. For example, patients who intended to receive a neoadjuvant chemotherapy and

Full access

Willemieke P.M. Dijksterhuis, Anouk E.J. Latenstein, Jessy Joy van Kleef, Rob H.A. Verhoeven, Jeanne H.M. de Vries, Marije Slingerland, Elles Steenhagen, Joos Heisterkamp, Liesbeth M. Timmermans, Marian A.E. de van der Schueren, Martijn G.H. van Oijen, Sandra Beijer and Hanneke W.M. van Laarhoven

because data on skeletal muscle mass and strength were unavailable. Treatment Analyses were stratified according to treatment type: (1) neoadjuvant chemoradiotherapy (nCRT) followed by a surgical resection, (2) neoadjuvant chemotherapy (nCT) followed by a